CTI BioPharma Corp. (CTIC)
| Market Cap | 244.53M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -45.64M |
| Shares Out | 73.71M |
| EPS (ttm) | -0.68 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 21 |
| Last Price | $3.27 |
| Previous Close | $3.12 |
| Change ($) | 0.15 |
| Change (%) | 4.81% |
| Day's Open | 3.14 |
| Day's Range | 3.10 - 3.29 |
| Day's Volume | 515,999 |
| 52-Week Range | 0.69 - 3.80 |
Innovation paid off big for investors.
SEATTLE, Dec. 8, 2020 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at The JMP Securities Hematology Summit at 3:00 p.m. ...
CTIC recently received FDA's accelerated approval go-ahead for pacritinib in MF patients with severe thrombocytopenia. This considerably reduces the risks associated with the company.
SEATTLE, Dec. 6, 2020 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced an oral presentation supporting the Company's pacritinib development program in the prevention of acute...
SEATTLE, Nov. 30, 2020 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced that an article highlighting pacritinib data was published in Blood Advances. The article, titled "Det...
CTI BioPharma Corp. (CTIC) CEO Adam Craig on Q3 2020 Results - Earnings Call Transcript
SEATTLE, Nov. 4, 2020 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced an oral presentation supporting the Company's pacritinib development program in graft versus host disea...
SEATTLE, Nov. 2, 2020 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its third quarter 2020 financial results on Tuesday, No...
CTI BioPharma (CTIC) news for Wednesday includes plans to submit a new drug application (NDA) sending CTIC stock soaring higher. The post CTI BioPharma News: Why CTIC Stock Is Skyrocketing 104...
CTI BioPharma: A Nano Cap With Interesting Prospects
SEATTLE, June 1, 2020 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced that it has enrolled the first patient in the Phase 3 PRE-VENT trial (NCT04404361) of pacritinib in hos...
SEATTLE, May 28, 2020 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Jefferies 2020 Healthcare Conf...
CTI Biopharma Accelerated Review, And Other News: The Good, Bad, And Ugly Of Biopharma
About CTIC
CTI BioPharma, a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It develops pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Vernalis (R&D) Limited. The company was formerly kno... [Read more...]
| Industry Biotechnology | IPO Date Mar 21, 1997 |
| CEO Adam Craig | Employees 25 |
| Stock Exchange NASDAQ | Ticker Symbol CTIC |
Financial Performance
In 2019, CTI BioPharma's revenue was $3.35 million, a decrease of -87.28% compared to the previous year's $26.29 million. Losses were -$40.02 million, 36.5% more than in 2018.
Analyst Forecasts
According to 4 analysts, the average rating for CTI BioPharma stock is "Buy." The 12-month stock price forecast is 7.70, which is an increase of 135.47% from the latest price.